March 26th, 2026 - Registration:
Session #1 Europe - Asia time: 9:00 AM CET - 4:00 JPT
Session #2 USA - Europe time: 11:00 AM EST - 5:00 PM CET
Agenda Highlights
While much of the industry focuses on screening faster and larger libraries, Iktos has taken a different approach: we don’t screen — we design.
In this webinar, we will present how reaction-based generative AI can fundamentally reshape early drug discovery by embedding synthetic feasibility directly into the molecular design process. Rather than generating molecules first and evaluating synthesizability later, our models integrate reaction knowledge upfront, ensuring that proposed compounds are both innovative and realistically accessible.
Through concrete case studies, we will illustrate how combining synthesis-aware GenAI with automated chemistry enables faster iteration cycles, higher-quality design proposals, and a shortened path from virtual concept to experimentally validated molecules.
-> In a recent peer-reviewed benchmark, our synthesis-aware generative models produced 85% synthetically accessible top-ranked candidates, compared to approximately 50% for REINVENT4. The practical impact is significant: novel, potent series (down to 30 nM) delivered in fewer than 30 synthesized compounds.
Attendees will gain insights into:
- The limitations of traditional virtual screening strategies
- How reaction-based generative AI integrates synthetic feasibility by design
- Benchmark data comparing synthesis-aware and classical generative approaches
- Real-world examples of rapid hit and lead generation
- How AI-driven design and automated synthesis work together to accelerate discovery
Join us to see how designing with synthesis in mind accelerates the journey from idea to validated molecule.
Speaker
Quentin Perron
Chief Scientific Officer & Co-founder, Iktos
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specialized in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.
